Enveric Biosciences, Inc.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
ENVB$1.51+4.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
| For the Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash Flows From Operating Activities: | ||
| Net loss | $(8,771,987) | $(9,574,987) |
| Adjustments to reconcile net loss to cash used in operating activities | ||
| Change in fair value of warrant liability | (858) | (24,370) |
| Change in fair value of investment option liability | (1,707) | (21,620) |
| Stock-based compensation | 827,323 | 1,562,392 |
| Deferred offering costs expensed | — | 418,200 |
| Amortization of intangibles | 42,182 | 168,750 |
| Depreciation expense | 158,676 | 168,739 |
| Other | (99,230) | — |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 250,938 | 178,496 |
| Accounts payable, accrued expenses and other liabilities | (413,864) | (834,630) |
| Due to related parties | (133,016) | 232,891 |
| Net cash used in operating activities | (8,141,543) | (7,726,139) |
| Cash Flows From Financing Activities: | ||
| Proceeds from sale of Common Stock and warrants, net of offering costs | 4,244,467 | — |
| Proceeds from Common Stock sold for cash pursuant to the ATM Agreement, net of offering costs | 1,636,799 | — |
| Proceeds from the exercise and inducement of Series A, B, C, and D warrants, net of offering costs | 4,698,241 | 2,676,980 |
| Proceeds from Common Stock sold under the Equity Distribution Agreement, net of offering costs | — | 2,290,186 |
| Proceeds from Common Stock sold under the Purchase Agreement, net of offering costs | — | 1,083,706 |
| Proceeds from the subscription receivable related to the issuance of Inducement Warrants and the exercise of warrants and preferred investment options | — | 1,804,819 |
| Payment for offering costs previously accrued | — | (181,857) |
| Net cash provided by financing activities | 10,579,507 | 7,673,834 |
| Effect of foreign exchange rate on changes on cash | (1,499) | 5,354 |
| Net increase (decrease) in cash | 2,436,465 | (46,951) |
| Cash at beginning of year | 2,241,026 | 2,287,977 |
| Cash at end of year | $4,677,491 | $2,241,026 |
| Supplemental disclosure of cash flow transactions: | ||
| Cash paid for interest | $— | $— |
| Income taxes paid | $— | $5,000 |
| Non-cash financing and investing activities: | ||
| Non-cash issuance of round-up shares | $860 | $— |
| Non-cash issuance of RSA vested shares | $393 | $— |
| Offering costs accrued not paid | $64,588 | $— |
| Deferred offering costs not paid | $5,000 | $— |
| Deemed dividend on inducement of warrants | $3,359,485 | $— |
| Issuance of Placement Agent Warrants as offering costs | $364,000 | $— |
| Issuance of common shares for offering costs | $— | $771,293 |
| Deferred offering costs charged to offering costs | $— | $612,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.